Abstract: Abstract: Atherosclerotic cardiovascular diseases (ASCVD) are the major causes of morbidity and mortality worldwide. Previous randomized controlled trials confirm that statin therapy can effectively reduce the level of low density lipoprotein cholesterol (LDL-C), all-cause and cardiovascular disease mortality in patients with and without ASCVD. However, there is no widespread use of lipid-lowering therapy to achieve the benefit in high risk patients with ASCVD and patients without ASCVD. Therefore, it is necessary to further elaborate the clinical benefits of statins and their combined use for lipid regulating therapy and increasing the beneficiaries.

Key words: Key words: coronary artery disease, dyslipidemias, cholesterol, LDL, statins, proprotein convertase subtilisin / kexin type 9 inhibitor, clinical benefit